COVID-19 erupted, mutated, and was supplemented by the challenges of monkeypox and the need to catch up with major treatment and immunisation backlogs accumulated during the pandemic.
At the same time, the industry must address the long-term difficulty of providing essential medicines and health services to the high percentage of global population that cannot access them because of costs.
The net effect has been to stimulate change in every aspect of the pharma industry – an industry not exactly known for its embrace of manufacturing innovation.
